Shares of Moderna Inc. (NASDAQ:MRNA) are trading slightly lower Wednesday morning, taking a brief pause after surging more than 150% following landmark clinical trial updates for its oncology pipeline. The modest retreat reflects routine profit-taking and consolidation as investors digest the recent momentum.
Moderna stock is among today’s weakest performers. Why is MRNA stock falling?
Oncology Pipeline Breakthrough Re-Energizes Long-Term Outlook
Despite the pullback Wednesday morning, market sentiment surrounding the biotechnology pioneer remains elevated following last week’s historic Phase 3 INTerpath-001 trial results.
Developed in partnership with Merck & Co, Moderna’s individualized mRNA cancer therapy, intismeran (V940/mRNA-4157), combined with Keytruda, demonstrated a statistically significant reduction in melanoma recurrence.
